{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:15:22Z","timestamp":1790302522289,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Institut Pasteur International Network Calmette & Yersin mobility"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Dihydroartemisinin\/piperaquine is increasingly used for the treatment of uncomplicated Plasmodium falciparum malaria in Africa. The efficacy of this combination in Cameroon is poorly documented, while resistance to dihydroartemisinin\/piperaquine readily spreads in Southeast Asia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study evaluated the clinical efficacy of dihydroartemisinin\/piperaquine in Cameroon, as well as the molecular profile and phenotypic susceptibility of collected isolates to dihydroartemisinin and piperaquine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Dihydroartemisinin\/piperaquine efficacy in 42\u2009days was followed-up for 138 patients presenting non-complicated falciparum malaria. Piperaquine concentration was determined at day 7 for 124 patients. kelch13 gene polymorphisms (n\u2009=\u2009150) and plasmepsin2 gene amplification (n\u2009=\u2009148) were determined as molecular markers of resistance to dihydroartemisinin and piperaquine, respectively. Parasite susceptibility to dihydroartemisinin and piperaquine was determined using validated in vitro survival assays.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The efficacy of dihydroartemisinin\/piperaquine treatment was 100% after PCR correction. The reinfections were not associated with a variation of piperaquine concentration at day 7. Ninety-six percent (144\/150) of the samples presented a WT allele of the kelch13 gene. Two percent (3\/150) presented the non-synonymous mutation A578S, which is not associated with resistance to dihydroartemisinin. No duplication of the plasmepsin2 gene was observed (0\/148). All the samples tested in vitro by survival assays (n\u2009=\u200987) were susceptible to dihydroartemisinin and piperaquine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dihydroartemisinin\/piperaquine has demonstrated excellent therapeutic efficacy with no evidence of emerging artemisinin or piperaquine resistance in Yaound\u00e9, Cameroon. This observation suggests that dihydroartemisinin\/piperaquine could be a sustainable therapeutic solution for P. falciparum malaria if implemented in areas previously free of artemisinin- and piperaquine-resistant parasites, unlike Southeast Asia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab281","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T13:41:05Z","timestamp":1630158065000},"page":"3037-3044","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of dihydroartemisinin\/piperaquine in patients with non-complicated <i>Plasmodium falciparum<\/i> malaria in Yaound\u00e9, Cameroon"],"prefix":"10.1093","volume":"76","author":[{"given":"M\u00e9lissa","family":"Mairet-Khedim","sequence":"first","affiliation":[{"name":"Malaria Translational Research Unit, Pasteur International Unit, Pasteur International Network, Phnom Penh, Cambodia and Paris, France"},{"name":"Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Universit\u00e9 Toulouse, CNRS UMR5051, INSERM UMR1291, UPS, Toulouse, France"},{"name":"Structural Microbiology Unit, Institut Pasteur, CNRS UMR 3528, 25 rue du Docteur Roux, 75724 Paris 15, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Nsango","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Facult\u00e9 de M\u00e9decine et des Sciences Pharmaceutiques, Universit\u00e9 de Douala, Douala, Cameroon"},{"name":"Malaria Research Unit, Centre Pasteur du Cameroon, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Ngou","sequence":"additional","affiliation":[{"name":"Malaria Research Unit, Centre Pasteur du Cameroon, Yaound\u00e9, Cameroon"},{"name":"MIVEGEC, IRD, CNRS, Univ. Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandie","family":"Menard","sequence":"additional","affiliation":[{"name":"Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Universit\u00e9 Toulouse, CNRS UMR5051, INSERM UMR1291, UPS, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Roesch","sequence":"additional","affiliation":[{"name":"Malaria Translational Research Unit, Pasteur International Unit, Pasteur International Network, Phnom Penh, Cambodia and Paris, France"},{"name":"Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimol","family":"Khim","sequence":"additional","affiliation":[{"name":"Malaria Translational Research Unit, Pasteur International Unit, Pasteur International Network, Phnom Penh, Cambodia and Paris, France"},{"name":"Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreynet","family":"Srun","sequence":"additional","affiliation":[{"name":"Malaria Translational Research Unit, Pasteur International Unit, Pasteur International Network, Phnom Penh, Cambodia and Paris, France"},{"name":"Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Iriart","sequence":"additional","affiliation":[{"name":"Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Universit\u00e9 Toulouse, CNRS UMR5051, INSERM UMR1291, UPS, Toulouse, France"},{"name":"Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Toulouse, H\u00f4pital Purpan, Toulouse F-31300, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lanot","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmacocin\u00e9tique et Toxicologie, Centre Hospitalier Universitaire de Toulouse, H\u00f4pital Purpan, Toulouse F-31300, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Otam","sequence":"additional","affiliation":[{"name":"Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Universit\u00e9 Toulouse, CNRS UMR5051, INSERM UMR1291, UPS, Toulouse, France"},{"name":"D\u00e9partement des Sciences Biom\u00e9dicales, Facult\u00e9 des Sciences, Universit\u00e9 de Ngaound\u00e9r\u00e9, Ngaound\u00e9r\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Abega","sequence":"additional","affiliation":[{"name":"Dispensaire de Nkol-Eton, BP894, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Ayong","sequence":"additional","affiliation":[{"name":"Malaria Research Unit, Centre Pasteur du Cameroon, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Morlais","sequence":"additional","affiliation":[{"name":"MIVEGEC, IRD, CNRS, Univ. Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Gandia","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmacocin\u00e9tique et Toxicologie, Centre Hospitalier Universitaire de Toulouse, H\u00f4pital Purpan, Toulouse F-31300, France"},{"name":"INTHERES, Universit\u00e9 de Toulouse, INRA, ENVT, BP 87614, 31076 Toulouse Cedex 3, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Witkowski","sequence":"additional","affiliation":[{"name":"Malaria Translational Research Unit, Pasteur International Unit, Pasteur International Network, Phnom Penh, Cambodia and Paris, France"},{"name":"Malaria Molecular Epidemiology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6626-7766","authenticated-orcid":false,"given":"Antoine","family":"Berry","sequence":"additional","affiliation":[{"name":"Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Universit\u00e9 Toulouse, CNRS UMR5051, INSERM UMR1291, UPS, Toulouse, France"},{"name":"Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Toulouse, H\u00f4pital Purpan, Toulouse F-31300, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"2021101808552195800_dkab281-B1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1473-3099(10)70096-7","article-title":"Changes in the burden of malaria in sub-Saharan Africa","volume":"10","author":"O\u2019Meara","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2021101808552195800_dkab281-B2"},{"key":"2021101808552195800_dkab281-B3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12936-014-0521-2","article-title":"Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children","volume":"14","author":"Nji","year":"2015","journal-title":"Malar J"},{"key":"2021101808552195800_dkab281-B4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1475-2875-9-56","article-title":"Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon","volume":"9","author":"Whegang","year":"2010","journal-title":"Malar J"},{"key":"2021101808552195800_dkab281-B5"},{"key":"2021101808552195800_dkab281-B6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/1475-2875-12-254","article-title":"A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in western Kenya","volume":"12","author":"Agarwal","year":"2013","journal-title":"Malar J"},{"key":"2021101808552195800_dkab281-B7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12936-018-2496-x","article-title":"A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali","volume":"17","author":"Dama","year":"2018","journal-title":"Malar J"},{"key":"2021101808552195800_dkab281-B8","doi-asserted-by":"crossref","first-page":"e2390","DOI":"10.1371\/journal.pone.0002390","article-title":"Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda","volume":"3","author":"Yeka","year":"2008","journal-title":"PLoS One"},{"key":"2021101808552195800_dkab281-B9","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","article-title":"Pyronaridine\u2013artesunate or dihydroartemisinin\u2013piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial","volume":"391","author":"Sagara","year":"2018","journal-title":"Lancet"},{"key":"2021101808552195800_dkab281-B10","doi-asserted-by":"crossref","first-page":"e6358","DOI":"10.1371\/journal.pone.0006358","article-title":"Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis","volume":"4","author":"Zwang","year":"2009","journal-title":"PLoS One"},{"key":"2021101808552195800_dkab281-B11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1475-2875-10-50","article-title":"Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children","volume":"10","author":"Nambozi","year":"2011","journal-title":"Malar J"},{"key":"2021101808552195800_dkab281-B12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014","journal-title":"Nature"},{"key":"2021101808552195800_dkab281-B13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","article-title":"A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study","volume":"17","author":"Witkowski","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021101808552195800_dkab281-B14","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41467-018-05652-0","article-title":"Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine","volume":"9","author":"Ross","year":"2018","journal-title":"Nat Commun"},{"key":"2021101808552195800_dkab281-B15","doi-asserted-by":"crossref","first-page":"e00303","DOI":"10.1128\/mBio.00303-17","article-title":"A variant PfCRT isoform can contribute to Plasmodium falciparum resistance to the first-line partner drug piperaquine","volume":"8","author":"Dhingra","year":"2017","journal-title":"mBio"},{"key":"2021101808552195800_dkab281-B16","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S1473-3099(19)30543-2","article-title":"Plasmodium falciparum resistance to piperaquine driven by PfCRT","volume":"19","author":"Dhingra","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021101808552195800_dkab281-B17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12936-019-2756-4","article-title":"African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker","volume":"18","author":"Leroy","year":"2019","journal-title":"Malar J"},{"key":"2021101808552195800_dkab281-B18","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3201\/eid2408.180370","article-title":"Plasmodium falciparum plasmepsin 2 duplications, West Africa","volume":"24","author":"Inoue","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"2021101808552195800_dkab281-B19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","article-title":"Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study","volume":"16","author":"Amaratunga","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2021101808552195800_dkab281-B20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMc1403007","article-title":"Dihydroartemisinin\u2013piperaquine failure in Cambodia","volume":"371","author":"Saunders","year":"2014","journal-title":"N Engl J Med"},{"key":"2021101808552195800_dkab281-B21","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1128\/AAC.00835-15","article-title":"Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment","volume":"59","author":"Leang","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021101808552195800_dkab281-B22","doi-asserted-by":"crossref","first-page":"e02731-18","DOI":"10.1128\/mBio.02731-18","article-title":"Global spread of mutant PfCRT and its pleiotropic impact on Plasmodium falciparum multidrug resistance and fitness","volume":"10","author":"Dhingra","year":"2019","journal-title":"mBio"},{"key":"2021101808552195800_dkab281-B23","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","article-title":"Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study","volume":"19","author":"van der Pluijm","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021101808552195800_dkab281-B24","year":"2009","journal-title":"Methods for Surveillance of Antimalarial Drug Efficacy"},{"key":"2021101808552195800_dkab281-B25","year":"2015","journal-title":"Guidelines for the Treatment of Malaria"},{"key":"2021101808552195800_dkab281-B26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4269\/ajtmh.2003.68.133","article-title":"Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of MSP-1, MSP-2, and GLURP","volume":"68","author":"Cattamanchi","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"2021101808552195800_dkab281-B27","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","article-title":"Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies","volume":"13","author":"Witkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2021101808552195800_dkab281-B28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/cpt.104","article-title":"Population pharmacokinetics of piperaquine in young Ugandan children treated with dihydroartemisinin-piperaquine for uncomplicated malaria","volume":"98","author":"Sambol","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2021101808552195800_dkab281-B29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12936-020-03281-x","article-title":"Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates","volume":"19","author":"Foguim","year":"2020","journal-title":"Malar J"},{"key":"2021101808552195800_dkab281-B30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/infdis\/jiv414","article-title":"Is the A578S single-nucleotide polymorphism in K13-propeller a marker of emerging resistance to artemisinin among Plasmodium falciparum in Africa?","volume":"213","author":"Ma\u00efga-Ascofar\u00e9","year":"2016","journal-title":"J Infect Dis"},{"key":"2021101808552195800_dkab281-B31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/1475-2875-13-431","article-title":"Mutations in Plasmodium falciparum K13 propeller gene from Bangladesh (2009-2013)","volume":"13","author":"Mohon","year":"2014","journal-title":"Malar J"},{"key":"2021101808552195800_dkab281-B32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jmii.2017.06.009","article-title":"Updates on k13 mutant alleles for artemisinin resistance in Plasmodium falciparum","volume":"51","author":"Zaw","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"2021101808552195800_dkab281-B34","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12936-016-1622-x","article-title":"Insight into k13-propeller gene polymorphism and ex vivo DHA-response profiles from Cameroonian isolates","volume":"15","author":"Menard","year":"2016","journal-title":"Malar J"},{"key":"2021101808552195800_dkab281-B35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1473-3099(18)30068-9","article-title":"Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study","volume":"18","author":"Amato","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021101808552195800_dkab281-B36","doi-asserted-by":"crossref","first-page":"e08714","DOI":"10.7554\/eLife.08714","article-title":"Genomic epidemiology of artemisinin resistant malaria","volume":"5","year":"2016","journal-title":"eLife"},{"key":"2021101808552195800_dkab281-B37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12936-019-2916-6","article-title":"Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa?","volume":"18","author":"Foguim Tsombeng","year":"2019","journal-title":"Malar J"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/3037\/40641401\/dkab281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/3037\/40641401\/dkab281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T20:26:07Z","timestamp":1634761567000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/11\/3037\/6359119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,8,28]]},"published-print":{"date-parts":[[2021,10,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab281","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,8,28]]}}}